Medexus Pharmaceuticals Inc MDP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CAD 1.77
- Day Range
- CAD 1.73–1.84
- 52-Week Range
- CAD 1.12–3.53
- Bid/Ask
- CAD 1.78 / CAD 1.82
- Market Cap
- CAD 43.78 Mil
- Volume/Avg
- 44,208 / 53,440
Key Statistics
- Price/Earnings (Normalized)
- 4.91
- Price/Sales
- 0.25
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Medexus Pharmaceuticals Inc is an innovative and rare disease pharmaceutical company with a strong North American commercial platform and a portfolio of proven best-in-class products. The company’s focus is on the therapeutic areas of hematology, auto-immune diseases, and allergy.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 98
- Website
- https://www.medexus.com
Valuation
|
Metric
|
MDP
|
|---|---|
Price/Earnings (Normalized) | 4.91 |
Price/Book Value | 1.12 |
Price/Sales | 0.25 |
Price/Cash Flow | 2.34 |
Price/Earnings
MDP
Financial Strength
|
Metric
|
MDP
|
|---|---|
Quick Ratio | 0.46 |
Current Ratio | 1.11 |
Interest Coverage | 0.94 |
Quick Ratio
MDP
Profitability
|
Metric
|
MDP
|
|---|---|
Return on Assets (Normalized) | 3.40% |
Return on Equity (Normalized) | 24.35% |
Return on Invested Capital (Normalized) | 18.36% |
Return on Assets
MDP
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Fspcrfpks | Qzm | $76.2 Bil | |
MKKGY
| Merck KGaA ADR | Lnsfvwzl | Bgydbj | $70.9 Bil | |
HLN
| Haleon PLC ADR | Jbvvrhcm | Fcwf | $37.8 Bil | |
VTRS
| Viatris Inc | Msvpbcgw | Wwrnb | $14.0 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Fqdzrdxv | Qmw | $12.7 Bil | |
CTLT
| Catalent Inc | Pccnzkw | Dswzwsr | $10.2 Bil | |
PRGO
| Perrigo Co PLC | Hyftjrw | Rfr | $4.4 Bil | |
CURLF
| Curaleaf Holdings Inc | Fsfjnwj | Klyfn | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Qhfxbxgkl | Pplyms | $3.5 Bil | |
GTBIF
| Green Thumb Industries Inc | Sbcfvvhhnt | Qpjw | $3.1 Bil |